✨ Free AI Report
Editas Medicine, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Editas Medicine, Inc.
Company Research

Editas Medicine, Inc.: Business Overview, Financials & Competitive Analysis

Editas Medicine, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Early-stage CRISPR gene editing company with promising preclinical data and strategic partnerships, but significant clinical and financial execution risks ahead. The company reported a trailing twelve-month net loss of $237.1M and negative operating cash flow of $210.3M, reflecting typical clinical-stage biotech burn rates. However, the company maintains a current.

What is Editas Medicine, Inc.'s industry? Editas Medicine, Inc. (editasmedicine.com) operates in Biological product (except diagnostic) manufacturing within the broader therapeutic biotechnology sector. AskCyborg classifies Editas Medicine, Inc. under Biological product (except diagnostic) manufacturing within the broader therapeutic biotechnology sector in its company registry.

Editas Medicine is a genome-editing company developing transformative genomic medicines using a proprietary CRISPR technology platform including CRISPR/Cas9, CRISPR/Cas12a, and foundational intellectual property for b...

4/ 10Mixed

Cyborg Score thesis

Early-stage CRISPR gene editing company with promising preclinical data and strategic partnerships, but significant clinical and...

Read the full analyst-debate transcript →
Industry Biological product (except diagnostic) manufacturing within the broader therapeutic biotechnology sector
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Editas Medicine, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Editas Medicine, Inc.

AskCyborg analysts argue the bull and bear cases for Editas Medicine, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Editas Medicine, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Editas Medicine, Inc. Overview

Pro stress-test →

Editas Medicine is a genome-editing company developing transformative genomic medicines using a proprietary CRISPR technology platform including CRISPR/Cas9, CRISPR/Cas12a, and foundational intellectual property for both systems. The company is a clinical-stage gene editing company focused on in vivo CRISPR-based medicines, positioning itself at the forefront of precision genetic medicine.

Strategic Profile

Pro stress-test →

Editas's lead in vivo development candidate, EDIT-401, is designed as a one-time treatment for hyperlipidemia through LDLR gene editing and has shown substantial LDL-C reductions in preclinical models. The company engages in collaborations, including with Bristol Myers Squibb and Vertex Pharmaceuticals, while advancing its pipeline. Its differentiation lies in proprietary lipid nanoparticle delivery and gene upregulation strategies targeting liver and blood cell therapies.

Competitive Landscape

Pro stress-test →

Editas competes within the gene editing space against Beam Therapeutics, Intellia Therapeutics, Caribou Biosciences, Prime Medicine, Fate Therapeutics, Sangamo Therapeutics, Precision BioSciences, and others. The competitive advantage hinges on proprietary CRISPR platform efficiency, delivery mechanisms, and clinical trial success timelines in the nascent field.

Industry Context

Editas Medicine, Inc. operates in Biological product (except diagnostic) manufacturing within the broader therapeutic biotechnology sector.

Key facts

Founded: 2013 · Headquarters: Cambridge, US · Employees: 246 · Revenue: $0.03B · Market cap: $0.21B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Editas Medicine, Inc..

  • EDIT-401 demonstrates potential as a best-in-class, one-time lipid treatment through in vivo LDLR gene editing
  • Lead development candidate selection planned for September 2025 with IND filing targeted by mid-2026 and human proof-of-concept expected by year-end 2026
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026: Company achieved 58% mean editing at five months post-dose, demonstrating therapeutically relevant editing levels with clinical validation
  • May 2025: U.S. Court of Appeals affirmed key intellectual property position
  • +1 moreTrack every material event for Editas Medicine, Inc. as it happens. Explore monitoring →
Get alerted when Editas Medicine, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

CRISPR Gene EditingBase editing and epigenetic modulation→CRISPR Gene EditingIn vivo CRISPR medicine platform→CRISPR Gene EditingZinc finger nuclease genome editing→

Compare Editas Medicine, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Editas Medicine, Inc. operates in Biological product (except diagnostic) manufacturing within the broader therapeutic biotechnology sector. See how the rest of the sector scores on the Cyborg framework.

Browse Biological product (except diagnostic) manufacturing within the broader therapeutic biotechnology sector research →
NEW · MCP server

Ask your AI assistant about Editas Medicine, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Editas Medicine, Inc. and its top competitor on Cyborg Score”
“What did Editas Medicine, Inc. do this quarter?”
“Is Editas Medicine, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Editas Medicine, Inc. do?+
Editas Medicine is a genome-editing company developing transformative genomic medicines using a proprietary CRISPR technology platform including CRISPR/Cas9, CRISPR/Cas12a, and foundational intellectual property for b...
What is Editas Medicine, Inc.'s Cyborg Score?+
Editas Medicine, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Editas Medicine, Inc.'s main competitors?+
Named competitors include CRISPR Gene Editing, CRISPR Gene Editing, CRISPR Gene Editing. The full competitive landscape is in the AskCyborg report.
How can I get the full Editas Medicine, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Editas Medicine, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Editas Medicine, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biological product (except diagnostic) manufacturing within the broader therapeutic biotechnology sector research

Companies in the same sector and named competitors, ranked by Cyborg Score.

4Editas Medicine, Inc.